Under construction – not a live service
Sign in
Taking people in FranceNo phase

Tests psychomotor therapy with usual treatment for depression

Tests psychomotor therapy with usual care in adults with depression.

Plain-language title generated from the registry record
Registry title: Impact of Psychomotor Therapy on the Quality of Life in Depression

Key facts

Where
Limoges, FranceSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 20 and 60 years old?

Source: NCT06234176, who can take part

Where in France

  • CH EsquirolLimoges, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Centre Hospitalier Esquirol
Trial code
NCT06234176
Record updated
30 October 2026
Original description
The effectiveness of psychomotor therapy in improving clinical outcomes or quality of life for individuals with depression is unclear.Read full original descriptionShow less

Influence of Psychomotor Therapy on Quality of Life in Patients With a Major Depressive Disorder: a Randomized Controlled Trial

The effectiveness of psychomotor therapy in improving clinical outcomes or quality of life for individuals with depression is unclear.

The investigators will assess how the participants' quality of life and psychomotor profile change over time.

The study aims to compare the quality of life at 3 months between patients who received 3 months of personalised psychomotor therapy in addition to standard treatment and those who received standard treatment alone.

The study lasted for 6 months, and the investigators expects a total of 128 people to participate in this research across several hospital establishments. This study evaluates the effectiveness of two types of treatment, divided into two randomly selected groups.

To participate, individuals must have a medical diagnosis of major depressive disorder (MDD) and be between the ages of 20 and 60.

They must have depressive symptoms with an HDRS score greater than 16 and provide informed consent. They must be treated or hospitalised at the Centre Hospitalier Esquirol or the Centre Hospitalier Henri Laborit (France).

After providing consent, they will undergo an initial clinical interview that evaluates anxiety, self-esteem, pleasure, and quality of life. The therapist assessed the participant's muscle tone, gross motor skills, praxis, manual dexterity, rhythm, processing of sensory information, and body image.

Following the assessment, the participant was randomly assigned to either the experimental or control group.

The experimental group received the usual treatment for depression and underwent psychomotor therapy once a week for 12 weeks.

The control group received the standard treatment for depression and underwent weekly telephone interviews.

An assessment is scheduled at 1 month to evaluate the participant's health status, including any changes to treatment and assessment of anxiety and depressive symptoms.

Another interim check-up is scheduled at 3 months to assess the patient's health status. The interview will also assess any changes to treatment, anxiety and depressive symptoms, quality of life, and psychomotor function.

A final visit will be scheduled at 6 months for an assessment of the participant's health. The interview will also assess any changes to treatment, anxiety and depressive symptoms, quality of life, and psychomotor function.

Inclusion: Diagnosis of depressive episode according to DSM-5 criteria; HDRS > 16; Hospitalized or followed-up in one of the participating centers; Affiliated or beneficiary of a social security scheme; Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).

Exclusion: Psychiatric comorbidity (non-tobacco addiction, eating disorders, bipolar disorder, obsessive-compulsive disorder, schizophrenia and related disorders); Sensory impairment or proven neurological pathology; History of neurological brain damage (including stroke, tumor, trauma resulting in loss of consciousness lasting more than 10 minutes); Limited functional ability (difficulty in moving about, performing manual tasks or moving about); Inability to understand questionnaires and study information; Inability to travel to the inclusion center (personal vehicle, public transport); Pregnant or breast-feeding women, on declaration; Forced hospitalization, subjects under guardianship or trusteeship, lack of social protection.

ClinicalTrials.gov NCT06234176